Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
Phytother Res ; 38(4): 1799-1814, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38330236

ABSTRACT

Futoquinol (Fut) is a compound extracted from Piper kadsura that has a nerve cell protection effect. However, it is unclear whether Fut has protective effects in Alzheimer's disease (AD). In this study, we aimed to explore the therapeutic effect of Fut in AD and its underlying mechanism. UPLC-MS/MS method was performed to quantify Fut in the hippocampus of mice brain. The cognition ability, neuronal and mitochondria damage, and levels of Aß1-42, Aß1-40, p-Tau, oxidative stress, apoptosis, immune cells, and inflammatory factors were measured in Aß25-35-induced mice. The content of bacterial meta-geometry was predicted in the microbial composition based on 16S rDNA. The protein levels of HK II, p-p38MAPK, and p38MAPK were detected. PC-12 cells were cultured in vitro, and glucose was added to activate glycolysis to further explore the mechanism of action of Fut intervention in AD. Fut improved the memory and learning ability of Aß25-35 mice, and reduced neuronal damage and the deposition of Aß and Tau proteins. Moreover, Fut reduced mitochondrial damage, the levels of oxidative stress, apoptosis, and inflammatory factors. Fut significantly inhibited the expression of HK II and p-p38MAPK proteins. The in vitro experiment showed that p38MAPK was activated and Fut action inhibited after adding 10 mM glucose. Fut might inhibit the activation of p38MAPK through the glycolysis pathway, thereby reducing oxidative stress, apoptosis, and inflammatory factors and improving Aß25-35-induced memory impairment in mice. These data provide pharmacological rationale for Fut in the treatment of AD.


Subject(s)
Alzheimer Disease , Gastrointestinal Microbiome , Lignans , Animals , Mice , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Apoptosis , Chromatography, Liquid , Gastrointestinal Microbiome/drug effects , Glucose/pharmacology , Lignans/pharmacology , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Peptide Fragments/adverse effects , Peptide Fragments/metabolism , Tandem Mass Spectrometry
2.
Oxid Med Cell Longev ; 2021: 1020614, 2021.
Article in English | MEDLINE | ID: mdl-34616501

ABSTRACT

Astragaloside IV (AS-IV) is an active component in Astragalus membranaceus with the potential to treat neurodegenerative diseases, especially Alzheimer's diseases (ADs). However, its mechanisms are still not known. Herein, we aimed to explore the systematic pharmacological mechanism of AS-IV for treating AD. Drug prediction, network pharmacology, and functional bioinformatics analyses were conducted. Molecular docking was applied to validate reliability of the interactions and binding affinities between AS-IV and related targets. Finally, experimental verification was carried out in AßO infusion produced AD-like phenotypes to investigate the molecular mechanisms. We found that AS-IV works through a multitarget synergistic mechanism, including inflammation, nervous system, cell proliferation, apoptosis, pyroptosis, calcium ion, and steroid. AS-IV highly interacted with PPARγ, caspase-1, GSK3Β, PSEN1, and TRPV1 after docking simulations. Meanwhile, PPARγ interacts with caspase-1, GSK3Β, PSEN1, and TRPV1. In vivo experiments showed that AßO infusion produced AD-like phenotypes in mice, including impairment of fear memory, neuronal loss, tau hyperphosphorylation, neuroinflammation, and synaptic deficits in the hippocampus. Especially, the expression of PPARγ, as well as BDNF, was also reduced in the hippocampus of AD-like mice. Conversely, AS-IV improved AßO infusion-induced memory impairment, inhibited neuronal loss and the phosphorylation of tau, and prevented the synaptic deficits. AS-IV prevented AßO infusion-induced reduction of PPARγ and BDNF. Moreover, the inhibition of PPARγ attenuated the effects of AS-IV on BDNF, neuroflammation, and pyroptosis in AD-like mice. Taken together, AS-IV could prevent AD-like phenotypes and reduce tau hyperphosphorylation, synaptic deficits, neuroinflammation, and pyroptosis, possibly via regulating PPARγ.


Subject(s)
Alzheimer Disease/prevention & control , Astragalus propinquus/chemistry , Drugs, Chinese Herbal/administration & dosage , Neuroinflammatory Diseases/prevention & control , Phenotype , Phytotherapy/methods , Saponins/administration & dosage , Triterpenes/administration & dosage , Alzheimer Disease/chemically induced , Alzheimer Disease/metabolism , Amyloid beta-Peptides/administration & dosage , Amyloid beta-Peptides/adverse effects , Animals , Computational Biology/methods , Disease Models, Animal , Drugs, Chinese Herbal/metabolism , Hippocampus/metabolism , Male , Mice , Mice, Inbred C57BL , Molecular Docking Simulation/methods , Network Pharmacology/methods , Neuroinflammatory Diseases/chemically induced , Neuroinflammatory Diseases/metabolism , PPAR gamma/metabolism , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Phosphorylation/drug effects , Pyroptosis/drug effects , Saponins/metabolism , Signal Transduction/drug effects , Support Vector Machine , Triterpenes/metabolism , tau Proteins/metabolism
3.
Sci Rep ; 10(1): 8124, 2020 05 15.
Article in English | MEDLINE | ID: mdl-32415207

ABSTRACT

Alzheimer's disease (AD) is a disease characterized by cerebral neuronal degeneration and loss in a progressive manner. Amyloid beta (Aß) in the brain is toxic to neurons, being a main risk factor for initiation and continuation of cognitive deterioration in AD. Neurotoxicity of Aß origin is also linked to oxidative stress characterized by excessive lipid peroxidation, protein oxidation, changes in antioxidant systems, and cerebral DNA damage in AD. Furthermore, Aß can induce oxidative neuronal cell death by a mitochondrial dysfunction. Cellular injury caused by oxidative stress can be possibly prevented by boosting or promoting bodily oxidative defense system by supplying antioxidants in diet or as medications. However, most synthetic antioxidants are found to have cytotoxicity, which prevents their safe use, and limits their administration. For this reason, more attention has been paid to the natural non-toxic antioxidants. One of the most promising groups of non-toxic antioxidative compounds is thought to be polysaccharides. This study investigated the characterization and protective action exerted by exopolysaccharides (EPSs) originated from Lactobacillus delbrueckii ssp. bulgaricus B3 and Lactobacillus plantarum GD2 to protect from apoptotic activity exerted by Aß1-42 among SH-SY5Y cells. We characterized EPSs by elemental analysis, FTIR, AFM, SEM, and XRD. The antioxidant effects of EPSs were determined by the DPPH free radical scavenging activity, hydroxyl radical scavenging activity, metal ion chelating activity, lipid peroxidation inhibitory activity, and superoxide anion scavenging activity method. The protective effects of EPSs were determined by flow cytometry and RT-PCR. Mannose ratio, molecular weight, functional groups, surface morphology, and amorphous character structure of EPSs are thought to play a role in the protective effect of EPSs. EPSs reduced apoptotic activity of Aß1-42 in addition to their depolarizing effect on mitochondrial membrane potential in concentration-dependent manner. These observations contribute the inclusion of EPSs among the therapeutic options used to manage various neurological disorders in the traditional medicine in a scientific manner, indicating that EPSs may be promising natural chemical constituents that need advanced research and development for pharmacological therapy of AD.


Subject(s)
Amyloid beta-Peptides/adverse effects , Antioxidants/pharmacology , Apoptosis , Lactobacillales/metabolism , Neuroblastoma/drug therapy , Neuroprotective Agents/pharmacology , Peptide Fragments/adverse effects , Polysaccharides, Bacterial/pharmacology , Humans , Lipid Peroxidation , Membrane Potential, Mitochondrial , Neuroblastoma/chemically induced , Neuroblastoma/pathology , Oxidation-Reduction , Oxidative Stress , Tumor Cells, Cultured
4.
Exp Anim ; 69(3): 269-278, 2020 Aug 05.
Article in English | MEDLINE | ID: mdl-32051390

ABSTRACT

A combination of aged garlic, ginger, and chili peppers extracts (AGC) was studied by high-performance liquid chromatography, 2,2-diphenyl-1-picrylhydrazyl, and ferric-reducing antioxidant assays, and oxidative stress markers were analyzed in Aß1-42-induced rats. The AGC was orally administered to Wistar rats at doses of 125, 250, and 500 mg/kg body weight (AGC125, AGC250, AGC500, respectively) for 64 days. At day 56, Aß1-42 was injected via both sides of the lateral ventricles. The effects of the AGC on spatial and recognition memory were examined using a Morris water maze and novel object recognition tasks. Rats induced with Aß1-42 exhibited obvious cognitive deficits, as demonstrated by their increased escape latency time (ET) and decreased retention time (RT) and percentage of discriminative index (DI). When compared with the control group, all AGC-treated rats showed significantly shorter ETs and higher DIs during the 5-min delay testing phase. Rats treated with AGC250 also had significantly longer RTs. Administration of Aß1-42 significantly increased malondialdehyde (MDA) levels and decreased superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) levels in the rat brain homogenate. Pretreatment with the AGC caused significant increases in SOD, GPx, and CAT activities, as well as a significant decrease in MDA in the rat brain homogenates after Aß-induced neurotoxicity. Our results suggested that an AGC may ameliorate cognitive dysfunction in Aß-treated rats due to its role in the upregulation of SOD, GPx, and CAT.


Subject(s)
Amyloid beta-Peptides/adverse effects , Antioxidants/metabolism , Brain/metabolism , Capsicum/chemistry , Cognition/drug effects , Garlic/chemistry , Peptide Fragments/adverse effects , Plant Extracts/pharmacology , Zingiber officinale/chemistry , Animals , Catalase/metabolism , Glutathione Peroxidase/metabolism , Male , Rats, Wistar , Spatial Memory/drug effects , Superoxide Dismutase/metabolism
5.
Pharmacol Res Perspect ; 7(6): e00547, 2019 12.
Article in English | MEDLINE | ID: mdl-31832205

ABSTRACT

Activation of MrgX2, an orphan G protein-coupled receptor expressed on mast cells, leads to degranulation and histamine release. Human MrgX2 binds promiscuously to structurally diverse peptides and small molecules that tend to have basic properties (basic secretagogues), resulting in acute histamine-like adverse drug reactions of injected therapeutic agents. We set out to identify MrgX2 orthologues from other mammalian species used in nonclinical stages of drug development. Previously, the only known orthologue of human MrgX2 was from mouse, encoded by Mrgprb2. MrgX2 genes of rat, dog (beagle), minipig, pig, and Rhesus and cynomolgus monkey were identified by bioinformatic approaches and verified by their ability to mediate calcium mobilization in transfected cells in response to the classical MrgX2 agonist, compound 48/80. The peptide GSK3212448 is an inhibitor of the PRC2 epigenetic regulator that caused profound anaphylactoid reactions upon intravenous infusion to rat. We showed GSK3212448 to be a potent MrgX2 agonist particularly at rat MrgX2. We screened sets of drug-like molecules and peptides to confirm the highly promiscuous nature of MrgX2. Approximately 20% of drug-like molecules activated MrgX2 (pEC50 ranging from 4.5 to 6), with the principle determinant being basicity. All peptides tested of net charge +3 or greater exhibited agonist activity, including the cell penetrating peptides polyarginine (acetyl-Arg9-amide) and TAT (49-60), a fragment of HIV-1 TAT protein. Finally, we showed that the glycopeptide antibiotic vancomycin, which is associated with clinical pseudo-allergic reactions known as red man syndrome, is an agonist of MrgX2.


Subject(s)
Anaphylaxis/chemically induced , Mast Cells/drug effects , Nerve Tissue Proteins/agonists , Peptide Fragments/adverse effects , Receptors, G-Protein-Coupled/agonists , Receptors, Neuropeptide/agonists , Vancomycin/adverse effects , Anaphylaxis/immunology , Animals , Cell Degranulation/drug effects , Cell Degranulation/immunology , Cell Line, Tumor , Cell-Penetrating Peptides/administration & dosage , Cell-Penetrating Peptides/adverse effects , Disease Models, Animal , Drug Evaluation, Preclinical/adverse effects , HEK293 Cells , Histone-Lysine N-Methyltransferase/antagonists & inhibitors , Humans , Mast Cells/immunology , Mast Cells/metabolism , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/immunology , Nerve Tissue Proteins/metabolism , Peptide Fragments/administration & dosage , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/immunology , Receptors, G-Protein-Coupled/metabolism , Receptors, Neuropeptide/genetics , Receptors, Neuropeptide/immunology , Receptors, Neuropeptide/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/metabolism , Syndrome , Vancomycin/administration & dosage , p-Methoxy-N-methylphenethylamine/pharmacology
6.
Food Funct ; 10(10): 6803-6814, 2019 Oct 16.
Article in English | MEDLINE | ID: mdl-31577306

ABSTRACT

Obesity induced by high-fat diet (HFD) and accumulation of amyloid beta (Aß) are known as a risk factor of Alzheimer's disease. We previously identified isoquercitrin (IQ) as an active compound of Acer okamotoanum. In the present study, we investigated the protective effects of the active ethyl acetate (EtOAc) fraction from A. okamotoanum and IQ on HFD and Aß25-35-induced cognitive impairment mice. C57BL/6J mice were fed with HFD for 10 weeks and then Aß25-35 was injected intracerebroventricularly (i.c.v.). The EtOAc fraction of A. okamotoanum and IQ were administered orally for 4 weeks at 100 and 10 mg kg-1 day-1, respectively. Learning and memory functions were evaluated using behavioral tests including T-maze, object recognition and Morris water maze tests. The HFD and Aß25-35 injection significantly impaired cognitive and memory function. However, administration of A. okamotoanum and IQ improved spatial cognitive ability and object recognition ability in T-maze and novel object recognition tests. In addition, A. okamotoanum and IQ-administered groups showed enhanced learning and memory function compared with HFD and Aß25-35-induced cognitive impairment mice in the Morris water maze test. Furthermore, administration of A. okamotoanum and IQ attenuated oxidative stress in the brain via inhibition of reactive oxygen species production, lipid peroxidation, and nitric oxide formation. Therefore, we suggest that A. okamotoanum and IQ improve HFD- and Aß25-35-induced cognitive impairment by inhibition of oxidative stress, and A. okamotoanum and IQ might be potential candidates for prevention and treatment of obesity- and Aß-induced cognitive impairment.


Subject(s)
Acer/chemistry , Amyloid beta-Peptides/adverse effects , Cognition/drug effects , Cognitive Dysfunction/drug therapy , Diet, High-Fat/adverse effects , Oxidative Stress/drug effects , Quercetin/analogs & derivatives , Administration, Oral , Alzheimer Disease/prevention & control , Animals , Brain , Cognitive Dysfunction/chemically induced , Disease Models, Animal , Lipid Peroxidation , Male , Maze Learning/drug effects , Memory/drug effects , Mice , Mice, Inbred C57BL , Peptide Fragments/adverse effects , Plant Extracts/pharmacology , Quercetin/pharmacology
7.
J Nat Med ; 73(1): 154-162, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30377903

ABSTRACT

Neuronal cell death induced by amyloid-ß (Aß) oligomers is implicated in neuronal degeneration and is a leading cause of Alzheimer's disease (AD). Therefore, to identify effective therapeutic agents for AD, we investigated the neuroprotective effects of two naturally occurring retinoid X receptor (RXR) agonists (SPF1 and SPF2), isolated from the root of Sophora tonkinensis Gagnep., on the Aß25-35-induced cytotoxicity against nerve growth factor-differentiated rat pheochromocytoma (PC12) cells. Pretreatment with SPFs significantly prevented Aß25-35-induced apoptosis in PC12 cells, similarly to the synthetic RXR agonist bexarotene. These effects were blocked by the RXR antagonist PA452. When the effects of SPFs were studied in the presence of the liver X receptor (LXR) agonist T0901317, the protective effects of SPFs were enhanced, suggesting that RXR/LXR heterodimers may play a key role in the neuroprotective effects of SPFs. SPFs and T0901317 induced ATP-binding cassette transporter 1 (ABCA1) protein expression in PC12 cells when administered alone or in combination. Intriguingly, a functional inhibitor of ABCA1 cyclosporine A negated the neuroprotective effects of SPFs or T0901317. Taken together, these results demonstrate that the RXR agonists SPF1 and SPF2 protect PC12 cells from Aß25-35-induced neurotoxicity in an RXR-dependent manner and that their effects are markedly enhanced by the LXR agonist T0901317, in part related to ABCA1 function. These results suggest a novel approach to the treatment or prevention of AD.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/adverse effects , Neuroprotective Agents/therapeutic use , PC12 Cells/metabolism , Peptide Fragments/adverse effects , Retinoid X Receptors/therapeutic use , Sophora/chemistry , Alzheimer Disease/pathology , Animals , Humans , Neuroprotective Agents/pharmacology , Rats , Retinoid X Receptors/agonists , Retinoid X Receptors/pharmacology
8.
J Oleo Sci ; 67(11): 1443-1453, 2018.
Article in English | MEDLINE | ID: mdl-30404965

ABSTRACT

The current investigation aimed to scrutinize the neuro-protective effect of hyperforin on ß­amyloid peptide (Aß)1-42 and H2O2 induced injury in PC12 cells and colchicine induced Alzheimer's disease (AD). PC12 cells were treated with H2O2 and (Aß)1-42 in the presence of hyperforin. The cell viability was determined via suing the MTT assay; malondialdehyde (MDA) and lactate dehydrogenase (LDH) levels were also scrutinized. Colchicine induced the destruction of memory and learning which was exhibited in neurobehavioral theory (passive avoidance and Morris water maze) connected with reduced activity of acetylcholinesterase (AChE). Anti­oxidant and inflammatory parameters also estimated. Hyperforin dose dependently increased the cell viability and reduced the MDA and LDH release via PC12 cell injured with H2O2 and (Aß)1-42. Hyperforin treatment lead to a considerable enhance in TLT in the retention trials as comparisian to acquisition trial suggesting as boosting memory and learning in rats. Hyperforin treatments significantly increase the AChE and reduced the superoxide dismutase, glutathione, MDA, protein carbonyl, glutathione peroxdiase, catalase, NF­kB and IL­1ß at dose dependent manner. In summary, the model of H2O2 and (Aß)1-42 induced PC12 cell injury was successfully developed and dose dependently treatment of hypoforin showed the neuroprotective effect against the H2O2 and (Aß)1-42 induced cell damage. These finding clearly exhibited that hyperforin reverted the colchicine induced neuro­chemical and behavioural alteration via potent anti­inflammatory and anti­oxidant activity.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/adverse effects , Antioxidants , Apoptosis/drug effects , Colchicine/adverse effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Peptide Fragments/adverse effects , Phloroglucinol/analogs & derivatives , Terpenes/pharmacology , Acetylcholinesterase/metabolism , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , L-Lactate Dehydrogenase/metabolism , Male , Malondialdehyde/metabolism , NF-kappa B/metabolism , Neuroprotective Agents/therapeutic use , PC12 Cells , Phloroglucinol/pharmacology , Phloroglucinol/therapeutic use , Rats , Rats, Wistar , Signal Transduction/drug effects , Terpenes/therapeutic use
9.
J Physiol Biochem ; 74(4): 647-654, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30232707

ABSTRACT

To fight against metabolic disorders such as insulin resistance, new alimentary behaviors are developed. For instance, hyperproteined, gluten-free, or collagen-enriched diets could be preconized in order to reduce the consequences of obesity. In this aim, this study evaluates the potential effects of warm sea fish collagen peptides (Naticol®) on representative metabolic and inflammatory parameters. For that, male C57Bl6/J mice fed with either a chow- (CD) or high-fat diet (HFD) were submitted or not to specific collagen peptides in drinking water (4 g/kg bw/d) for 20 weeks. Weight, body composition, glucose tolerance, and insulin sensitivity were followed up. Effects of fish collagen peptides on various blood parameters reflecting the metabolism status were also measured (free fatty acids, triglycerides, cholesterol, hormones) together with adipocyte inflammation. Results showed that HFD-fed mice supplemented by fish collagen peptides exhibited a significant lower increase in body weight as soon as the twelfth week of treatment whereas no effect of the peptide was observed in CD fed mice. In line with this result, a weaker increase in fat mass in HFD-fed mice supplemented with Naticol® at both 9 and 18 weeks of treatment was also observed. In spite of this resistance to obesity promoted by fish collagen peptides treatment, no difference in glucose tolerance was found between groups whereas mice treated with Naticol® exhibited a lower basal glycemia. Also, even if no effect of the treatment on adipocyte lipolysis was found, a decrease of inflammatory cytokines was retrieved in collagen-supplemented group arguing for a potential better insulin sensitivity. Altogether, these results need to be completed but are the first describing a benefic role of warm sea fish collagen peptides in a context of metabolic disease paving the route for a potential utilization in human obesity-associated disorders.


Subject(s)
Anti-Obesity Agents/therapeutic use , Collagen/therapeutic use , Dietary Supplements , Fish Proteins, Dietary/therapeutic use , Insulin Resistance , Obesity/therapy , Peptide Fragments/therapeutic use , Adipose Tissue/immunology , Adipose Tissue/metabolism , Animals , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anti-Obesity Agents/adverse effects , Anti-Obesity Agents/chemistry , Anti-Obesity Agents/metabolism , Apelin/agonists , Apelin/genetics , Apelin/metabolism , Collagen/adverse effects , Collagen/chemistry , Collagen/metabolism , Cytokines/antagonists & inhibitors , Cytokines/genetics , Cytokines/metabolism , Diet, High-Fat/adverse effects , Dietary Supplements/adverse effects , Fish Proteins, Dietary/adverse effects , Fish Proteins, Dietary/chemistry , Fish Proteins, Dietary/metabolism , Gene Expression Regulation , Glucose Intolerance/etiology , Glucose Intolerance/immunology , Glucose Intolerance/prevention & control , Lipolysis , Male , Mice, Inbred C57BL , Obesity/etiology , Obesity/metabolism , Obesity/physiopathology , Panniculitis/etiology , Panniculitis/immunology , Panniculitis/prevention & control , Peptide Fragments/adverse effects , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Weight Gain
10.
Nutrients ; 10(7)2018 Jun 26.
Article in English | MEDLINE | ID: mdl-29949889

ABSTRACT

Collagen-peptide supplementation could be an effective remedy to improve hydration, elasticity, and wrinkling in human skin. The aim of this study was to conduct a double-blind, randomized, placebo-controlled trial to clinically evaluate the effect on human skin hydration, wrinkling, and elasticity of Low-molecular-weight Collagen peptide (LMWCP) with a tripetide (Gly-X-Y) content >15% including 3% Gly-Pro-Hyp. Individuals (n = 64) were randomly assigned to receive either placebo or 1000 mg of LMWCP once daily for 12 weeks. Parameters of skin hydration, wrinkling, and elasticity were assessed at baseline and after 6 weeks and 12 weeks. Compared with the placebo group, skin-hydration values were significantly higher in the LMWCP group after 6 weeks and 12 weeks. After 12 weeks in the LMWCP group, visual assessment score and three parameters of skin wrinkling were significantly improved compared with the placebo group. In case of skin elasticity, one parameter out of three was significantly improved in the LMWCP group from the baseline after 12 weeks, while, compared with the placebo group, two parameters out of three in the LMWCP group were higher with significance after 12 weeks. In terms of the safety of LMWCP, none of the subjects presented adverse symptoms related to the test material during the study period. These results suggest that LMWCP can be used as a health functional food ingredient to improve human skin hydration, elasticity, and wrinkling.


Subject(s)
Collagen Type I/administration & dosage , Dietary Supplements , Oligopeptides/administration & dosage , Peptide Fragments/administration & dosage , Protein Hydrolysates/administration & dosage , Skin Aging/drug effects , Skin/drug effects , Administration, Oral , Adult , Collagen Type I/adverse effects , Dietary Supplements/adverse effects , Double-Blind Method , Elasticity , Female , Humans , Middle Aged , Molecular Weight , Oligopeptides/adverse effects , Peptide Fragments/adverse effects , Protein Hydrolysates/adverse effects , Skin/metabolism , Time Factors , Treatment Outcome , Water/metabolism
11.
Am J Chin Med ; 46(2): 389-405, 2018.
Article in English | MEDLINE | ID: mdl-29433392

ABSTRACT

Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. Although the exact causes of AD have not yet been fully elucidated, cholinergic dysfunction, mitochondrial damage, oxidative stress and neuroinflammation have been recognized as influential factors. Current drugs that are designed to address only a single target are unable to mitigate or prevent the progression of this complicated disease, so new disease-modifying drugs are urgently needed. Chinese herbs with thousand years of effective usage might be a good source for potential drugs. Gardenia jasminoides J. Ellis (Fructus Gardenia) is a common traditional Chinese medicine with tranquilizing effects, which is an important component of widely-used traditional Chinese medicine for dementia. GJ-4 is crocin richments extracted from Gardenia jasminoides J. Ellis. In our study, we attempted to observe the effects of GJ-4 on learning and memory injury induced by amyloid-[Formula: see text] 25-35 (A[Formula: see text] injection in mice. Treatment with GJ-4 dose-dependently enhanced the memory and cognition ability of A[Formula: see text]-injected mice. Preliminary mechanistic studies revealed the protective effect of GJ-4 was related to its protection of neurons and cholinergic dysfunction. The mechanistic results also indicated that GJ-4 could enhance antioxidant capacity and attenuate neuroinflammation. Our results implied that GJ-4 might be a promising drug to improve cognitive and memory impairment, with multiple targets.


Subject(s)
Amyloid beta-Peptides/adverse effects , Antioxidants , Carotenoids/pharmacology , Carotenoids/therapeutic use , Cognitive Dysfunction/chemically induced , Cognitive Dysfunction/prevention & control , Gardenia/chemistry , Peptide Fragments/adverse effects , Phytotherapy , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Animals , Carotenoids/isolation & purification , Cognitive Dysfunction/psychology , Disease Models, Animal , Fruit/chemistry , Learning/drug effects , Male , Memory/drug effects , Mice, Inbred ICR , Plant Extracts/isolation & purification
12.
Planta Med ; 84(11): 820-828, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29301146

ABSTRACT

The polyphenol compound, oxyresveratrol (OXY) possesses potent antioxidant and neuroprotective properties of potential utility in the treatment of Alzheimer's disease. However, the low oral bioavailability limits its neuroprotective effect and clinical application. The neuroprotective effect of orally administered OXY-loaded self-microemulsifying drug delivery system (OXY-SMEDDS) was compared with free OXY in vivo. Mice were orally administered either free OXY or OXY-SMEDDS once daily at a dose of 90, 180, or 360 mg/kg for 14 d. Mice received a single intracerebroventricular injection of the neurotoxic amyloid ß (Aß)25 - 35 peptide at day 8 during oral treatment. The OXY-SMEDDS formulation resulted in four-times reduction of the free OXY dose required for prevention of neurotoxicity effects due to Aß25 - 35 peptide as demonstrated by a significant decline in behavior impairments, lipid oxidation levels, and neuronal cell loss in all hippocampal subfields (p < 0.0001). These results indicate the potential of OXY-SMEDDS by oral delivery to improve the efficacy of this compound in the treatment of Alzheimer's disease.


Subject(s)
Alzheimer Disease/prevention & control , Amyloid beta-Peptides/adverse effects , Antioxidants/pharmacology , Artocarpus/chemistry , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Stilbenes/pharmacology , Administration, Oral , Animals , Antioxidants/chemistry , Biological Availability , Drug Delivery Systems , Emulsions , Hippocampus/drug effects , Male , Mice , Mice, Inbred ICR , Neuroprotective Agents/chemistry , Peptide Fragments/adverse effects , Plant Extracts/chemistry , Rats, Wistar , Stilbenes/chemistry
13.
J Med Food ; 21(3): 225-232, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29373070

ABSTRACT

Obesity is generally associated with low-grade chronic inflammation that involves the recruitment of macrophages and other inflammation factors to the adipocytes of obese individuals. Tumor necrosis factor-alpha (TNF-α), a cytokine associated with systemic inflammation, is elevated in conditions of obesity. TNF-α is an important factor that plays an important role in skeletal muscle wasting. Apoptosis of myonuclei contributes to the loss of muscle mass and therefore plays an important role in skeletal muscle atrophy. In mouse models that were fed a high fat diet (HFD), a lipolysis-stimulating peptide-VHVV (purified from hydrolysate resulting from flavourzyme treatment of soy protein) was found to reduce HFD-related apoptotic effects in mice skeletal muscle and potentially control atrophy. HFD fed mice had heavier body weight than those fed with normal chow, and VHVV administration restricted lipid accumulation in muscle tissues of mice fed with HFD but increased nutrient uptake. Moreover, specific concentrations of VHVV regulated TNF-α expression that was elevated by HFD, suppressed apoptosis-related proteins and regulated the proteins of lipid metabolism.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Apoptosis/drug effects , Lipolysis/drug effects , Muscle, Skeletal/drug effects , Muscular Atrophy/prevention & control , Oligopeptides/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/metabolism , Biomarkers/metabolism , Body Weight/drug effects , Diet, High-Fat/adverse effects , Dose-Response Relationship, Drug , Energy Intake/drug effects , Injections, Intraperitoneal , Male , Mice, Inbred C57BL , Muscle, Skeletal/immunology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Atrophy/etiology , Muscular Atrophy/metabolism , Muscular Atrophy/pathology , Obesity/chemically induced , Obesity/etiology , Obesity/immunology , Obesity/physiopathology , Oligopeptides/administration & dosage , Oligopeptides/adverse effects , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Peptide Fragments/therapeutic use , Random Allocation , Soybean Proteins/administration & dosage , Soybean Proteins/adverse effects , Soybean Proteins/therapeutic use , Specific Pathogen-Free Organisms , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolism
14.
J Sci Food Agric ; 97(2): 551-555, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27097525

ABSTRACT

BACKGROUND: The present study aimed to investigate the in vivo antihypertensive effect on spontaneously hypertensive rats (SHRs) induced by egg protein-derived peptide QIGLF, which has been previously characterized in vitro as a potent angiotensin-converting enzyme inhibitor. RESULTS: In vivo antihypertensive effect of QIGLF orally administered was evaluated by the tail-cuff method. The systolic blood pressure and the diastolic blood pressure of rats were measured 0, 5, 10, 15 and 20 h after administration every day. Subsequently, the effect of QIGLF on angiotensin-converting enzyme mRNA expression in the kidney of SHRs was evaluated by a polymerase chain reaction. Systolic blood pressure was found to be reduced markedly in the SHRs after a single oral administration. CONCLUSION: The results show that the effect of QIGLF (50 mg kg-1 body weight) was similar to that of captopril (10 mg kg-1 body weight) with respect to lowering systolic blood pressure in SHRs. Therefore, egg white protein-derived peptide QIGLF may be useful in the prevention or treatment of hypertension. © 2016 Society of Chemical Industry.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , Dietary Supplements , Egg Proteins/therapeutic use , Hypertension/diet therapy , Kidney/physiopathology , Oligopeptides/therapeutic use , Peptide Fragments/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Captopril/adverse effects , Captopril/therapeutic use , Dietary Supplements/adverse effects , Egg Proteins/administration & dosage , Egg Proteins/adverse effects , Enzyme Repression , Hypertension/drug therapy , Hypertension/metabolism , Hypertension/physiopathology , Kidney/metabolism , Male , Oligopeptides/administration & dosage , Oligopeptides/adverse effects , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Peptidyl-Dipeptidase A/chemistry , Peptidyl-Dipeptidase A/genetics , Peptidyl-Dipeptidase A/metabolism , RNA, Messenger/metabolism , Rats, Inbred SHR , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
15.
Crit Rev Food Sci Nutr ; 57(2): 335-343, 2017 Jan 22.
Article in English | MEDLINE | ID: mdl-26067872

ABSTRACT

Current opinion strongly links nutrition and health. Among nutrients, proteins, and peptides which are encrypted in their sequences and released during digestion could play a key role in improving health. These peptides have been claimed to be active on a wide spectrum of biological functions or diseases, including blood pressure and metabolic risk factors (coagulation, obesity, lipoprotein metabolism, and peroxidation), gut and neurological functions, immunity, cancer, dental health, and mineral metabolism. A majority of studies involved dairy peptides, but the properties of vegetal, animal, and sea products were also assessed. However, these allegations are mainly based on in vitro and experimental studies which are seldom confirmed in humans. This review focused on molecules which were tested in humans, and on the mechanisms explaining discrepancies between experimental and human studies.


Subject(s)
Dietary Proteins/metabolism , Dietary Supplements , Food Handling , Models, Biological , Peptides/metabolism , Protein Hydrolysates/metabolism , Animals , Dietary Proteins/adverse effects , Dietary Proteins/therapeutic use , Dietary Supplements/adverse effects , Digestion , Fermentation , Humans , Meat/adverse effects , Milk Proteins/adverse effects , Milk Proteins/metabolism , Peptide Fragments/adverse effects , Peptide Fragments/metabolism , Peptide Fragments/therapeutic use , Peptides/adverse effects , Peptides/therapeutic use , Protein Hydrolysates/adverse effects , Protein Hydrolysates/therapeutic use , Protein Stability , Reproducibility of Results , Seafood/adverse effects
16.
J Sci Food Agric ; 97(3): 918-922, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27218227

ABSTRACT

BACKGROUND: Spirulina platensis is an excellent source of proteins (>60%) that can be hydrolyzed into bioactive peptides. RESULTS: In this study, whole proteins of Spirulina platensis were extracted and hydrolyzed using three gastrointestinal endopeptidases (pepsin, trypsin and chymotrypsin). Subsequently, gel filtration chromatography was employed to separate hydrolysates, and four fractions (Tr1-Tr4) were obtained. Among them, Tr2 showed the strongest anti-proliferation activities on three cancer cells (MCF-7, HepG-2 and SGC-7901), with IC50 values of <31.25, 36.42 and 48.25 µg mL-1 , respectively. Furthermore, a new peptide, HVLSRAPR, was identified from fraction Tr1. This peptide exhibited strong inhibition on HT-29 cancer cells with an IC50 value of 99.88 µg mL-1 . CONCLUSION: Taken together, these peptides possessed anti-proliferation activities on cancer cells and low cytotoxicity on normal cells, suggesting that they might serve as a natural anticancer agent for nutraceutical and pharmaceutical industries. © 2016 Society of Chemical Industry.


Subject(s)
Algal Proteins/isolation & purification , Anticarcinogenic Agents/isolation & purification , Bacterial Proteins/isolation & purification , Drug Discovery , Hepatocytes/drug effects , Neoplasms/prevention & control , Spirulina/chemistry , Algal Proteins/adverse effects , Algal Proteins/chemistry , Algal Proteins/pharmacology , Amino Acid Sequence , Anticarcinogenic Agents/adverse effects , Anticarcinogenic Agents/chemistry , Anticarcinogenic Agents/pharmacology , Bacterial Proteins/adverse effects , Bacterial Proteins/chemistry , Bacterial Proteins/pharmacology , Cell Line , Cell Line, Tumor , Cell Proliferation/drug effects , China , Chymotrypsin/metabolism , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Colonic Neoplasms/prevention & control , Dietary Supplements/adverse effects , Hepatocytes/cytology , Hepatocytes/metabolism , Humans , Molecular Weight , Neoplasms/metabolism , Neoplasms/pathology , Oligopeptides/adverse effects , Oligopeptides/chemistry , Oligopeptides/isolation & purification , Oligopeptides/pharmacology , Pepsin A/metabolism , Peptide Fragments/adverse effects , Peptide Fragments/chemistry , Peptide Fragments/isolation & purification , Peptide Fragments/pharmacology , Protein Hydrolysates/chemistry , Trypsin/metabolism
17.
J Agric Food Chem ; 64(17): 3353-61, 2016 May 04.
Article in English | MEDLINE | ID: mdl-27079470

ABSTRACT

To examine the antiamnesic effects of broccoli (Brassica oleracea var. italica) leaves, we performed in vitro and in vivo tests on amyloid beta (Aß)-induced neurotoxicity. The chloroform fraction from broccoli leaves (CBL) showed a remarkable neuronal cell-protective effect and an inhibition against acetylcholinesterase (AChE). The ameliorating effect of CBL on Aß1-42-induced learning and memory impairment was evaluated by Y-maze, passive avoidance, and Morris water maze tests. The results indicated improving cognitive function in the CBL group. After the behavioral tests, antioxidant effects were detected by superoxide dismutase (SOD), oxidized glutathione (GSH)/total GSH, and malondialdehyde (MDA) assays, and inhibition against AChE was also presented in the brain. Finally, oxo-dihydroxy-octadecenoic acid (oxo-DHODE) and trihydroxy-octadecenoic acid (THODE) as main compounds were identified by quadrupole time-of-flight ultraperformance liquid chromatography (Q-TOF UPLC-MS) analysis. Therefore, our studies suggest that CBL could be used as a natural resource for ameliorating Aß1-42-induced learning and memory impairment.


Subject(s)
Amyloid beta-Peptides/adverse effects , Brassica/chemistry , Learning Disabilities/prevention & control , Memory Disorders/prevention & control , Peptide Fragments/adverse effects , Plant Extracts/pharmacology , Plant Leaves/chemistry , Animals , Chromatography, Liquid , Learning Disabilities/etiology , Male , Mass Spectrometry , Memory Disorders/etiology , Mice , Mice, Inbred ICR , PC12 Cells , Rats
18.
Life Sci ; 149: 153-9, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26898126

ABSTRACT

Anxiety disorders are major health problems in terms of costs stemming from sick leave, disabilities, healthcare and premature mortality. Despite the availability of classic anxiolytics, some anxiety disorders are still resistant to treatment, with higher rates of adverse effects. In this respect, several toxins isolated from arthropod venoms are useful in identifying new compounds to treat neurological disorders, particularly pathological anxiety. Thus, the aims of this study were to identify and characterize an anxiolytic peptide isolated from the venom of the social wasp Polybia paulista. The peptide was identified as Polisteskinin R, with nominal molecular mass [M+H](+)=1301Da and primary structure consisting of Ala-Arg-Arg-Pro-Pro-Gly-Phe-Thr-Pro-Phe-Arg-OH. The anxiolytic effect was tested using the elevated plus maze test. Moreover, adverse effects on the spontaneous behavior and motor coordination of animals were assessed using the open field and rotarod tests. Polisteskinin R induced a dose-dependent anxiolytic effect. Animals treated with the peptide and diazepam spent significantly more time into the open arms when compared to the groups treated with the vehicle and pentylenetetrazole. No significant differences in spontaneous behavior or motor coordination were observed between the groups, showing that the peptide was well tolerated. The interaction by agonists in both known BK receptors induces a variability of physiological effects; Polisteskinin R can act on these receptors, inducing modulatory activity and thus, attenuating anxiety behaviors. The results of this study demonstrated that the compound Polisteskinin R exerted potent anxiolytic effects and its analogues are promising candidates for experimental pharmacology.


Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Bradykinin/therapeutic use , Peptide Fragments/therapeutic use , Wasp Venoms/therapeutic use , Animals , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/isolation & purification , Anxiety/psychology , Bradykinin/adverse effects , Bradykinin/isolation & purification , Drug Evaluation, Preclinical/methods , Male , Peptide Fragments/adverse effects , Peptide Fragments/isolation & purification , Rats , Rats, Wistar , Wasp Venoms/adverse effects , Wasp Venoms/isolation & purification
19.
Pharmacol Biochem Behav ; 139(Pt A): 47-58, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26484504

ABSTRACT

Crocin, as a carotenoid, is one of the main and active constituents of saffron stigmas (Crocus sativus L.) that is widely used in folk medicine. Several studies have pointed out the potent antioxidant and neuroprotective properties of crocin which may have therapeutic values for management of neurodegenerative disorders such as Alzheimer's disease. Alzheimer's disease is the most common form of dementia among the elderly and is characterized by massive neuronal loss and progressive cognitive impairment. Beta amyloid hypothesis is the main theoretical research framework for Alzheimer's disease which states that extracellular aggregation of beta amyloid results in synaptic loss and eventually cell apoptosis. Recent findings suggest that autophagy and apoptosis are extensively involved in Alzheimer's disease. In order to investigate therapeutic values of crocin, we examined the effect of crocin on memory, cell apoptosis, and autophagy using in vivo models of Alzheimer's disease. We also compared the effect of crocin administration on spatial memory with nicotine as positive control. Morris water maze results show that intra-peritoneal and intra-hippocampal administration of crocin significantly improve spatial memory indicators such as escape latency, traveled distance and time spent in target quadrant when compared to beta amyloid injection. Furthermore, we measured certain biomarkers of cell autophagy and apoptosis using Western blot analysis. Our results reveal that crocin administration does not cause any significant alteration in Beclin-1 and ratio of LC3-II/LC3-I compared to the group received beta amyloid by hippocampal injection. However, in contrast to autophagy, crocin administration significantly decreases Bax/Bcl-2 ratio and cleaved Caspase-3 level. This demonstrates that crocin inhibits beta amyloid induced apoptosis, which is possibly associated with its antioxidant properties. Our results further confirm the neuroprotective properties of crocin as a potential pharmaceutical agent for management of Alzheimer's disease.


Subject(s)
Amyloid beta-Peptides/antagonists & inhibitors , Apoptosis Regulatory Proteins/metabolism , Apoptosis/drug effects , Autophagy/drug effects , Carotenoids/therapeutic use , Memory Disorders/drug therapy , Peptide Fragments/antagonists & inhibitors , Amyloid beta-Peptides/administration & dosage , Amyloid beta-Peptides/adverse effects , Animals , Behavior, Animal/drug effects , Carotenoids/administration & dosage , Carotenoids/pharmacology , Hippocampus/drug effects , Hippocampus/metabolism , Memory Disorders/chemically induced , Microinjections , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacokinetics , Neuroprotective Agents/therapeutic use , Nicotine/pharmacology , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects
20.
BMC Complement Altern Med ; 15: 55, 2015 Mar 11.
Article in English | MEDLINE | ID: mdl-25888276

ABSTRACT

BACKGROUND: Tong Luo Jiu Nao (TLJN), a modern formula of Chinese medicine extracts on the basis of Traditional Chinese Medicine theory, has been used to treat dementia. The present study aimed to investigate its ameliorating effects on Aß1-40-induced cognitive impairment in rats using a series of novel reward-directed instrumental learning (RDIL) tasks, and to determine its possible mechanism of action. METHODS: Rats were pretreated with TLJN extract (0.9 and 1.8 g/kg, p.o.) for 10 daysbefore surgery, and were trained to gain reward reinforcement by lever pressing at the meantime. Thereafter, rats received a bilateral microinjection of Aß1-40 in CA1 regions of the hippocampus. Cognitive performance was evaluated with the goal directed (higher response ratio) and habit (visual signal discrimination and extinction) learning tasks, as well as on the levels of biochemical parameters and molecules. RESULTS: Our findings first demonstrated that TLJN can improve Aß1-40-induced amnesia in RDIL via enhancing the comprehension of action-outcome association and the utilization of cue information to guide behavior. Then, its ameliorating effects should attribute to the modulation of ERK/CaMKII/CREB signaling in the hippocampus. CONCLUSION: TLJN can markedly enhance cognitions of Aß1-40 microinjection animal model in adaptive behavioral tasks. It has the potential, possibly as complementary and alternative therapy, to prevent and/or delay the deterioration of cognitive impairment in AD.


Subject(s)
Alzheimer Disease/drug therapy , Cognition Disorders/drug therapy , Cognition/drug effects , Drugs, Chinese Herbal/therapeutic use , Hippocampus/drug effects , Learning/drug effects , Phytotherapy , Adaptation, Psychological , Alzheimer Disease/metabolism , Amnesia/drug therapy , Amnesia/metabolism , Amyloid beta-Peptides/adverse effects , Amyloid beta-Peptides/metabolism , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Cognition Disorders/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , Dementia , Disease Models, Animal , Drugs, Chinese Herbal/pharmacology , Feedback, Psychological/drug effects , Hippocampus/metabolism , MAP Kinase Signaling System/drug effects , Male , Medicine, Chinese Traditional , Peptide Fragments/adverse effects , Peptide Fragments/metabolism , Rats, Wistar , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL